Literature DB >> 28035380

PROX1 promotes human glioblastoma cell proliferation and invasion via activation of the nuclear factor-κB signaling pathway.

Xuchang Xu1, Xuefeng Wan1, Xinting Wei2.   

Abstract

Prospero homeobox protein 1 (PROX1) is highly expressed in high-grade malignant astrocytic gliomas. However, the role of PROX1 in the pathogenesis of glioblastoma multiforme (GBM) remains unclear. The present study overexpressed PROX1 in human GBM cell lines and examined its effects on cell growth, tumorigenesis, and invasiveness. In addition, the involvement of the nuclear factor‑κB (NF‑κB) signaling pathway in the action of PROX1 was examined. It was identified that overexpression of PROX1 significantly increased the proliferation and colony formation of glioblastoma cells, compared with empty vector‑transfected controls. Furthermore, ectopic expression of PROX1 promoted the growth of GBM xenograft tumors. Western blot analysis revealed that PROX1 overexpression induced nuclear accumulation of NF‑κB p65 and upregulated the expression levels of the NF‑κB responsive genes cyclin D1 and matrix metallopeptidase 9. An NF‑κB reporter assay demonstrated that PROX1‑overexpressing glioblastoma cells had significantly greater NF‑κB‑dependent reporter activities compared with empty vector‑transfected controls. Transfection of a dominant inhibitor of κBα mutant into PROX1‑overexpressing cells significantly impaired their proliferation and invasion capacities, which was accompanied by reduced levels of nuclear NF‑κB p65. Collectively, these data indicated that PROX1 serves an oncogenic role in GBM and promotes cell proliferation and invasiveness potentially via activation of the NF‑κB signaling pathway. Therefore, PROX1 may represent a potential target for the treatment of GBM.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28035380     DOI: 10.3892/mmr.2016.6075

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  8 in total

1.  Circ_0007534 Silencing Inhibits the Proliferation, Migration and Invasion and Induces the Apoptosis of Glioma Cells Partly Through Down-Regulating PROX1 Via Elevating miR-22-3p Level.

Authors:  Yong Zheng; Yan Wang; Rongkang Mai; Liang Liu; Zifeng Zhu; Yiyao Cao
Journal:  Cell Mol Neurobiol       Date:  2021-09-18       Impact factor: 4.231

2.  miR-137 acts as a tumor suppressor via inhibiting CXCL12 in human glioblastoma.

Authors:  Dehua Li; Wei Shan; Yan Fang; Pan Wang; Jicheng Li
Journal:  Oncotarget       Date:  2017-08-24

3.  Molecular Signature of Prospero Homeobox 1 (PROX1) in Follicular Thyroid Carcinoma Cells.

Authors:  Magdalena Rudzińska; Małgorzata Grzanka; Anna Stachurska; Michał Mikula; Katarzyna Paczkowska; Tomasz Stępień; Agnieszka Paziewska; Jerzy Ostrowski; Barbara Czarnocka
Journal:  Int J Mol Sci       Date:  2019-05-05       Impact factor: 5.923

4.  Tailless/TLX reverts intermediate neural progenitors to stem cells driving tumourigenesis via repression of asense/ASCL1.

Authors:  Anna E Hakes; Andrea H Brand
Journal:  Elife       Date:  2020-02-19       Impact factor: 8.140

5.  PI3K Pathway Inhibition with NVP-BEZ235 Hinders Glycolytic Metabolism in Glioblastoma Multiforme Cells.

Authors:  Shreya Udawant; Carl Litif; Alma Lopez; Bonnie Gunn; Erin Schuenzel; Megan Keniry
Journal:  Cells       Date:  2021-11-07       Impact factor: 6.600

6.  Retracted Article: TRIM22 functions as an oncogene in gliomas through regulating the Wnt/β-catenin signaling pathway.

Authors:  Shi-Lei Tang; Yuan-Lin Gao; Wen-Zhong Hu
Journal:  RSC Adv       Date:  2018-09-03       Impact factor: 4.036

7.  The role of prospero homeobox 1 (PROX1) expression in follicular thyroid carcinoma cells.

Authors:  Magdalena Rudzinska; Joanna K Ledwon; Damian Gawel; Justyna Sikorska; Barbara Czarnocka
Journal:  Oncotarget       Date:  2017-12-12

Review 8.  The Impact of Transcription Factor Prospero Homeobox 1 on the Regulation of Thyroid Cancer Malignancy.

Authors:  Magdalena Rudzińska; Barbara Czarnocka
Journal:  Int J Mol Sci       Date:  2020-05-02       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.